---
title: "Vivos Therapeutics Q2 FY26 net loss widens to $5.52 million; revenue rises 35% to $5.2 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295972692.md"
description: "Vivos Therapeutics reported Q2 FY26 revenue of $5.2 million, a 35% increase year-over-year, driven by service revenue growth. However, the net loss widened to $5.52 million, though loss per share narrowed to $0.31. Gross margin improved to 57%, while operating loss remained flat at $4.83 million. Cash reserves decreased to $1.77 million, and stockholders’ equity deficit expanded to $3.82 million."
datetime: "2026-08-14T20:29:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295972692.md)
  - [en](https://longbridge.com/en/news/295972692.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295972692.md)
generator: "portal-rs"
---

# Vivos Therapeutics Q2 FY26 net loss widens to $5.52 million; revenue rises 35% to $5.2 million

-   Vivos Therapeutics posted Q2 revenue of $5.2 million, up 35% from a year earlier, as service revenue climbed to $3.8 million. \* Net loss widened to $5.52 million, while loss per share narrowed to $0.31. \* Gross margin rose 2 percentage points to 57%, while operating loss held roughly flat at $4.83 million. \* Cash and cash equivalents fell to $1.77 million at June 30, while stockholders’ equity deficit widened to $3.82 million. \* CEO Kirk Huntsman cited rising referrals and program revenue in Nevada centers, progress on SCN’s AI-enabled software conversion, and expanded capacity. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivos Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608141628PRIMZONEFULLFEED9810649) on August 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [VVOS.US](https://longbridge.com/en/quote/VVOS.US.md)

## Related News & Research

- [Vivos Therapeutics opens Henderson, Nevada sleep testing and treatment center, targets over $10 million annual capacity](https://longbridge.com/en/news/296505979.md)
- [Vivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript](https://longbridge.com/en/news/295983640.md)
- [Serbia Current Account Deficit Largest in 6 Months](https://longbridge.com/en/news/296431805.md)
- [Tobii schedules Q2 2026 interim report webcast presentation](https://longbridge.com/en/news/296061914.md)
- [REG - UIL Limited UIL Finance Ltd - Purchase of 2026 ZDP Shares](https://longbridge.com/en/news/296518280.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**